Skip to main content

Table 1 Mechanisms of novel drugs for UMCL used in the trials described

From: Current trials for frontline therapy of mantle cell lymphoma

BTK inhibitor

Ibrutinib

Acalabrutinib

Bgb-3111

Anti-CD20

Rituximab

Obinutuzumab

Ofatumumab

Tositumomab

Anti-B1 antibody

Ibritumomab

Alkylating agent

Bendamustine

Immuno-modulator

Thalidomide

Lenalidomide

Purine analog

Cladribine

Proteasome inhibitor

Bortezomib

mTOR inhibitor

Temsirolimus

Radioisotope

Iodine 131I Tositumomab

131I Anti-B1 antibody

90Y-Ibritumomab tiuxetan

  1. BTK Bruton’s tyrosine kinase, CDK cyclin-dependent kinase, mTOR mechanistic target of rapamycin